Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

Key Inclusion Criteria:

1. Men or women ≥18 years of age with type 1 or 2 diabetes mellitus who have moderatelysevere to severe nonproliferative diabetic retinopathy (NPDR) [(diabetic retinopathyseverity scale (DRSS) levels 47 or 53)], confirmed by the central reading center, inwhom panretinal photocoagulation (PRP) can be safely deferred for at least 6 monthsper the investigator

2. Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS)letter score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40or better)

Key Exclusion Criteria:

1. Presence of diabetic macular edema (DME) threatening the center of the macula in thestudy eye

2. Evidence of retinal neovascularization on clinical examination or FluoresceinAngiography (FA)

3. Any prior focal or grid laser photocoagulation or any prior PRP in the study eye

4. Any prior systemic anti-vascular endothelial growth factor (VEGF) treatment orintravitreal (IVT) anti-VEGF treatment in the study eye

5. Any prior intraocular steroid injection in the study eye

6. Current anterior segment neovascularization (ASNV), vitreous hemorrhage, or tractionalretinal detachment visible at the screening assessments in the study eye Note: Other inclusion/ exclusion criteria apply